Most patients with chronic immune thrombocytopenic purpura (ITP) have autoantibodies directed against the glycoprotein (GP) Ilb/llla complex. We have used a filamentous phage library that displays random linear hexapeptides t o identify peptide sequences recognized by these autoantibodies. Plasma antibody eluates from two patients were used t o select for phage displaying autoantibody-reactive peptides. From patient ITP-1 (known t o have two distinct autoantibodies), we identified anti-GPllb/llla antibody-specific phage encoding the peptide sequences Arg-Glu-Lys-AlaLys-Trp (REKAKW) and Pro-Val-Val-Trp-Lys-Asn (PVVWKN). Patient ITP-2 bound phage encoding the hexapeptide sequence Arg-Glu-Leu-Leu-Lys-Met. Each phage showed saturable dose-dependent binding t o immobilized autoantibody, and binding could be blocked with purified GPllb/llla. Patient ITP-1 autoantibody recognition of phage encoding REKAKW HRONIC IMMUNE thrombocytopenic purpura (ITP) is an autoimmune disorder in which autoantibodies against platelet membrane proteins result in platelet destruction by the reticuloendothelial system. Many antiplatelet autoantibodies bind to platelet glycoprotein (GP) IIb/IIIa,' although precise localization of the antigenic epitopes has only recently been investigated. The results of earlier studies in our laboratory showed that plasma antibodies from about 15% of ITP patients react with the carboxyterminal region (c-terminus) of GPIIIa.* Because this region of GPIIIa is on the cytoplasmic portion of the molecule, these anti-cterminus antibodies are more likely a secondary response to the exposure of cytoplasmic antigens during platelet destruction by other antibodies directed to surface antigens. The results of subsequent studies showed that platelet-associated autoantibodies, including those from patients with plasma anti-c-terminus autoantibody, react with other areas of the GPIIb/IIIa ~o m p l e x .~ These could be directed to antigens located on GPIIb or GPIIIa or to antigenic sites requiring regions of both subunits.
HRONIC IMMUNE thrombocytopenic purpura (ITP)
is an autoimmune disorder in which autoantibodies against platelet membrane proteins result in platelet destruction by the reticuloendothelial system. Many antiplatelet autoantibodies bind to platelet glycoprotein (GP) IIb/IIIa,' although precise localization of the antigenic epitopes has only recently been investigated. The results of earlier studies in our laboratory showed that plasma antibodies from about 15% of ITP patients react with the carboxyterminal region (c-terminus) of GPIIIa.* Because this region of GPIIIa is on the cytoplasmic portion of the molecule, these anti-cterminus antibodies are more likely a secondary response to the exposure of cytoplasmic antigens during platelet destruction by other antibodies directed to surface antigens. The results of subsequent studies showed that platelet-associated autoantibodies, including those from patients with plasma anti-c-terminus autoantibody, react with other areas of the GPIIb/IIIa ~o m p l e x .~ These could be directed to antigens located on GPIIb or GPIIIa or to antigenic sites requiring regions of both subunits.
Other investigators have also studied platelet antigens. Kekomaki et a14 noted that many patients have plasma autoantibodies that bind to a 50-kD cysteine-rich region of GPIIIa. He et a15 also studied plasma antibodies from ITP patients, and they reported that 83%, Sl%, 38%, and 28% of the plasma antibodies studied reacted with GPIb/IX, GPIIb/ IIIa, GPIV, and GPIa/IIa, respectively. Using adsorption techniques, they determined that the plasmas contained antibodies against both extracellular and cytosolic regions of GPIIb/IIIa or GPIb.' More recently, we studied platelet-associated anti-GPIIb/IIIa autoantibodies from chronic ITP patients and showed that cation chelation of GPIIb/IIIa prevented the binding of most of these antibodies, suggesting that they reacted with nonlinear epitopes.6 This finding has recently been confirmed.' Attempts to define autoantigens of platelet-associated autoantibodies using large recombinant GPIIIa peptides showed binding of only 1 of 31 antibodies tested, suggesting that the autoantigens were located on GPIIb or required an intact complex for their antigenicity.
To further evaluate antigens on the GPIIbAIIa complex, we have used a phage library that displays random linear hexapeptides.'"' In this library, degenerate synthetic oligonucleotides, encoding random peptides, are cloned into the fUSE5 phage vector where they are displayed as an aminoterminal fusion with the gene I11 coat protein at one tip of the virion. If one or more of the displayed peptides binds to an autoantibody, it can be selected from the nonbinding phage by a series of affinity purifications. The amino acid sequence of the bound phage can then be derived by phage amplification in Escherichia coli and sequencing the relevant portion of the viral DNA. Affinity selection with two ITP patient plasma autoantibodies identified two hexapeptide sequences that mimic autoantibody epitopes located within the cytoplasmic region of GPIIIa and one hexapeptide sequence that appears to mimic an epitope in the extracellular portion of GPIIb/IIIa and was found to bind to autoantibodies from two different ITP patients. This suggests that a limited number of ITP autoantibody epitopes exist and that they are shared by some ITP patients.
MATERIALS AND METHODS

Patients
We studied plasma anti-GPIIblIIIa antibody from two chronic ITP patients (ITP-1 and ITP-2). All chronic ITP patients were diagnosed using standard criteria.'' Each patient had severe disease, as shown by their failure to attain a complete remission with either corticoste-roids or splenectomy. The patient samples were chosen because they had high levels of anti-GPIIb/IIIa autoantibody as measured by the immunobead assay" and sufficient material to allow adequate study.
Preparation of Platelet-Associated and Plasma Antibody Eluates
Eluates were used so that most of the contaminating IgG could be removed before evaluation. Plasma antibodies were eluted from normal platelets that had been incubated for 2 hours at room temperature with patient plasma (2 X IO9 platelets/mL plasma) followed by washing. The washed platelets, which were incubated with patient plasma, were centrifuged, and the pellet was resuspended in 0.1 mol/ L glycine-HC1 (pH, 2.5) to a final concentration of 2 to 10 X 10' platelets/mL. After incubation at room temperature for 15 minutes and removal of the membranes by centrifugation, the supernatant fluid was neutralized with 1 m o m Tris (pH, 9) and dialyzed overnight against phosphate-buffered saline (PBS). Insoluble material was removed by centrifugation. Control eluates were prepared by acid eluting washed normal platelets in the same manner.
Monoclonal Antibodies
Antihuman IgG, Fc-specific HB43 was provided by American Type Culture Collection, (Rockville, MD), and anti-GPIIb (2A9) was provided by Dr Virgil Woods (University of California, San Diego, CA).
Construction of the Peptide Libraries
A linear hexapeptide library was constructed by one of us (R.B.) as previously reported." The fUSE 5 virions and E coli K91Kan were kindly provided by Dr Jamie Scott (The Scripps Research Institute, La Jolla, CA). A 70-base synthetic oligonucleotide [CTA-GCCGAAACTGTTGAA] , in which N signifies any deoxynucleotide and K signifies either G or T, was made double-stranded by polymerase chain reaction with the oligonucleotides CTATTCTCA-CTCGGCCGACG and TTCAACAGTTTCGGCCCCAG. The 70-bp PCR product was digested with B g l I to generate a 33-bp fragment containing a core degenerate coding sequence (NNK)6, which encodes for each of the 20 residues and an amber stop codon. The library was prepared by ligating the synthetic 33-bp Bgl I fragment into fUSE5 and transforming E coli MC1061 by electroporation. Each individual phage contains one of these random oligonucleotide sequences and will display the appropriate hexapeptide, flanked on the aminoterminus by Ala-Asp-Gly-Ala and on the carboxyterminus by the remainder of the gene I11 product. This library contains greater than 2 X 10' independent clones.
TTCTCACTCGGCCGACGGGGT (NNK)6 GGGGCCGCTGGG-
AfJinity Purijication of Phage Mimitopes Recognized by Autoantibody
Phage expressing autoantibody mimitopes were affinity-purified by sequential adsorptions to immobilized autoantibody. Plasma autoantibody eluate (100 pL) was added to an aliquot of phage library (phage concentration was adjusted to contain at least 100 copies of each random peptide in 0.1% bovine serum albumin [BSAIPBSTween), and the mixture was incubated overnight at 4°C. Then, 100 pL of a 1/2 dilution of staph-A agarose in either BSAPBS-Tween or 3% BLOTTO/PBS-Tween were added to each tube and incubated with constant mixing for 60 minutes at room temp. The BSA and BLOTTO were alternated to prevent purification of phage, which may bind to these proteins. The mixture was transferred to a 15-mL capped tube, and the sepharose (containing bound autoantibody and any bound phage) was washed 9 times with 10 mL of PBS-Tween and once with 10 mL of normal saline (to remove any buffering capacity). To the pellet was added 600 pL of elution buffer (0.1 N HC1, pH to 2.2, with glycine) and, after 15 minutes of incubation, the mixture was centrifuged for 2 minutes at 3000~. The supernatant fluid was aspirated, neutralized with 36 pL of 2 mol/L Tris-base (pH, 9.0), and added to 400 pL of E coli K91-Kan. After incubation for 15 minutes at 37"C, 9 mL of Superbroth was added, and the mixture was incubated at 37°C for 30 minutes with aeration. Next, 10 pL of tetracycline (200 pg/mL) was added, and the mixture was incubated for 60 minutes at 37°C. Dilutions to 10 ") were plated on LB-tetracycline plates, and the percent recovery was determined.
To amplify the selected phage, each 10-mL aliquot of infected bacterial suspension was added to a 500-mL flask containing 90 mL of Superbroth with tetracycline (12.5 pg/mL) and incubated overnight at 37°C with aeration. The bacteria were removed by centrifugation at 10,OOOg for 5 min at 4"C, and the phage were precipitated from the supernatant fluid by adding 4 g of polyethylene glycol-8ooO and 3 g NaCI, incubating on ice for 3 hours, and then centrifuging at 10,000g for 30 minutes at 4°C. The phage were resuspended in 2.5 mL of PBS/azide and titered. A total of four sequential affinity purifications were performed. Phage produced by individual bacterial colonies, harvested after the fourth purification, were tested for specificity as described below. Single-stranded DNA was isolated from purified phage and sequenced to determine the encoded peptide sequence.
Evaluation of Autoantibody Specijicity for the Panned Phage
Specificity was evaluated using 2 methods, (1) phage binding to autoantibody and lack of phage binding either to autoantibody that had been adsorbed with platelets or to control eluates and (2) blocking of phage binding to autoantibody by purified GPIIb/IIIa.
Microtiter wells were coated with murine monoclonal antihuman IgG (10 pg/mL) and, after blocking with 3% BLOTTO in PBSTween, 50 pL of one of the following were added: patient autoantibody eluate, control eluate, or patient autoantibody eluate that had been adsorbed with washed platelets and that no longer reacted with GPIIbfiIIa. After 2 hours of incubation and washing, 50 pL of 0.1% BSA-PBS-Tween containing a known quantity of affinity-purified or irrelevant phage was added to separate wells. Bound phage were detected by serial l-hour incubations (separated by washing) with 50 p L of rabbit anti-MI3 phage antibody, 50 pL of biotinylated donkey antirabbit antibody (Chemcon International, Temecula, CA), 50 pL of preformed complexes consisting of avidin and biotinylated horseradish peroxidase (ABC System; Vector Laboratories, Burlingame, CA), and 50 pL of substrate (0.7 pL/mL HzOz and 0.7 mg/ mL o-phenylenediamine dihydrochloride in 0.02 molL citric acid, 0.05 molL NaZHP04 [pH, 51). Net optical density after subtraction of control eluate values was determined. In selected studies, bound rabbit anti-M13 phage antibody was detected with '251-affinity-purified goat antirabbit antibody (Sigma Chemical CO, St Louis, MO).
In blocking studies, varying concentrations of purified GPIIb/IIIa (affinity-purified using monoclonal anti-GPIIb antibody [2A9] linked to sepharose) was added for 60 minutes before the addition of the phage. Otherwise, the assay was identical.
Blocking of Phage Binding to Autoantibody With Synthetic Peptides
Peptides were synthesized on a Gilson AMs422 by the Protein/ DNA Core Facility, The Scripps
Research Institute. The synthetic peptides were Gly-Ala-Arg-Glu-Lys-Ala-Lys-Trp-Gly-Ala (GAREKAKWGA) and Gly-Ala-Pro-Val-Val-Trp-Lys-Asn-GlyAla (GAPVVWKNGA). Microtiter wells coated with murine monoclonal antihuman IgG (HB43) and blocked with 3% BLOTTO were
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From incubated with patient autoantibody eluate for 2 hours. After washing, wells were incubated for 60 minutes with 40 pL of either synthetic peptide (800 pg/mL) or BSA (1 mg/mL). Next, 10 pL of purified phage was added, and the mixture was incubated for an additional 60 minutes. Bound phage were detected with rabbit anti-M13 phage antibody and 'Z51-affinity-purified goat antirabbit antibody as described above.
Binding of Autoantibody to GPIIIa Peptides
Thirty-nine overlapping biotinylated synthetic 10-residue peptides corresponding to amino acids of GPIIIa (Chiron Mimotopes, Victoria, Australia) were dissolved in dimethyl sulfoxide/40% acetonitrile per the manufacturer's instructions and used as a 111OOO final dilution in 0.1% BSA in PBS containing 0.1% azide. Separate microtiter wells were coated with 50 pL of streptavidin (5 pg/mL in water) and incubated overnight. After 6 washes with 0.05% Tween-20 in PBS (PBS-Tween), the wells were blocked for 60 minutes with 2% BSA-PES-Tween. After 6 washes, 50 pL of each peptide was added to separate wells, incubated for 2 hours, and washed 6 times. Next, 50 pL of patient antibody eluate was added and incubated for 2 hours. After washing, bound antibody was detected with '251-antihuman IgG (-200,000 cpdwell).
RESULTS
We studied plasma antibody eluates from two patients with chronic TTP (ITP-1 and -2). The two plasma antibodies were chosen for study, because it was known that a portion of the antibodies bound to the cytoplasmic fragment of GPIIIa' and would allow evaluation of the system.
Evaluation of Plasma Autoantibody Eluates
Patient ITP-I. Phage expressing two different hexapeptide sequences were affinity-isolated from the phage library on patient ITP-1 autoantibody. Both showed significant dose-dependent binding to the plasma autoantibody eluate from patient ITP-1 when compared with that for control eluates (Fig 1) . One phage expressed the amino acid sequence Arg-Glu-Lys-Ala-Lys-Trp (REKAKW), and the other expressed Pro-Val-Val-Trp-Lys-Asn (PVVWKN). Specificity of the binding of both phage was demonstrated by showing reduced binding to ITP-l plasma autoantibody that had been adsorbed with platelets and a dose-dependent decrease in the binding of both REKAKW and PVVWKN phage when the autoantibody eluate was preincubated with purified GPIIblIIIa (Fig 2) .
It is known from previously published studies that ITP-1 plasma contains autoantibodies to at least two distinct epitopes. One antibody binds to the cytoplasmic portion of GPIIIa, and the remaining antibody or antibodies bind to other regions of the GPIIbfiIIa heterodimer (patient ITP-3 in Fujisawa et a13). To further evaluate the epitopes represented by the phage REKAKW and PVVWKN, we preincubated a synthetic peptide, corresponding to amino acids 721-762 of the GPIIIa cytoplasmic fragment, with the ITP-l eluate before adding the phage. As shown in Fig 2, the synthetic cytoplasmic peptide blocked the binding of REKAKW to ITP-1 eluate but did not inhibit PVVWKN phage binding. This suggested that these phage reflected different epitopes and that the REKAKW was on the cytoplasmic fragment of GPIIIa. Additional studies were performed to confirm that phage REKAKW and phage PVVWKN bind to distinct anti-GPIIb/ IIIa autoantibodies. Phage binding studies were performed in which the patient's autoantibody eluate was preincubated with synthetic peptides containing either the REKAKW or PVVWKN sequence, before addition of the phage. As shown in Fig 3, the synthetic peptides blocked only phage containing the same sequence. Thus, these phage must reflect two distinct epitopes.
The REKAKW sequence was found to be homologous to a region of the GPIIIa cytoplasmic tail (Fig 4) . To ascertain if this homologous sequence was indeed an epitope for one of the autoantibodies from ITP-l, we evaluated the binding of this autoantibody to sequential 10-residue peptides from the GPIIIa cytoplasmic fragment. These studies show binding of ITP-1 antibody to five sequential overlapping peptides, all of which contained the sequence RARAKW (Fig 5) . This For personal use only. on August 30, 2017. by guest www.bloodjournal.org From
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Specificity of isolated hexapeptide display phage for ITP-1 anti-GPllb/llla autoantibody. Isolated fUSE5 phage l1 x 10" CFUlmL) expressing the hexapeptide sequences PWWKN or REKAKW were added t o microtiter wells containing immobilized autoantibodies from patient ITP-1 alone (0). in the presence of 75 pglmL purified GPllblllla (a), or in the presence of 500 FglmL GPllla cytoplasmic tail peptide (residues 721-7621 (W). Also shown, is fUSE5 phage binding to microtiter wells containing ITP-l antibody eluates that were pre-adsorbed with normal platelets (B). Bound phage were detected and quantitated as described in Materials and Methods. Results are expressed as the percentage of maximal binding t o ITP-1 autoantibody in the absence of any added inhibitor.
sequence is similar to the sequence REKAKW, displayed by the phage (Fig 4) . It seems likely that the first 3 amino acids are important for binding because, in previous studies, the antibody bound to the synthetic peptide (amino acids 721-744) containing the entire RARAKW sequence (GPIIIa 734-739) but not to one beginning with AKW (amino acids In summary, phage expressing the peptides REKAKW or PVVWKN bind to ITP-I autoantibody eluate. The REK-AKW appears to reflect a binding site on the cytoplasmic portion of GPIIIa, whereas PVVWKN mimics an epitope in another portion of GPIIb/IIIa.
Patient ITP-2. Similar studies were performed using plasma autoantibody eluate from another patient, ITP-2. This autoantibody was known to bind exclusively to the GPIIIa cytoplasmic region as shown by studies using GPIIb/IIIa recombinants expressed on Chinese hamster ovary cells. This patient's antibody bound strongly to the GPIIb/IIIa recombinant containing intact GPIIIa but did not bind to the recombinant that lacked the cytoplasmic portion of GPIIIa (patient ITP-6 in Fujisawa et A').
We isolated phage from the library, expressing the peptide Arg-Glu-Leu-Leu-Lys-Met (RELLKM), which bound strongly in a dose-dependent manner to the patient's plasma autoantibody eluate when compared with control eluates (Fig  1) . Tests for specificity showed (1) minimal reactivity of the phage with eluate that had been adsorbed with platelets to remove antibody reactivity and (2) marked inhibition of phage binding by purified GPIIbnIIa and by the synthetic 737-75 l).* BOWDITCH ET AL GPIIIa cytoplasmic peptide (residues 721-762; Fig 6) . The peptide sequence RELLKM is not represented in the cytoplasmic fragment. suggesting that this sequence represents a mimitope of the native epitope. The epitope may require a specific conformation or be made up from nonlinear sequences because this antibody did not bind to an isolated region when studied using sequential GPIIIa IO-residue peptides spanning the cytoplasmic portion of GPIIIa (data not shown). However, this autoantibody does bind to and is inhibited by the synthetic peptide corresponding to the amino acid sequence of the entire cytoplasmic region (amino acids 72 1-762).
Binding of Aflni~-Purified Phage t o Other ITP Autoantibodies
One of the goals of this project is to ultimately develop a panel of affinity-purified phage expressing multiple different epitopes (or mimitopes). This panel will be used to screen a large number of ITP autoantibodies to see if there are common epitopes. We have tested a small number of platelet-associated autoantibodies, from ITP patients other than those described above, with the three affinity-purified phage. As shown in Table 1 autoantibody with purified GPIIb/IIIa (100 yg/mL 57% blocking; 200 pg/mL, complete blocking). These results suggest that there may be a limited number of epitopes among ITP patients.
DISCUSSION
Most autoantibodies in patients with chronic ITP bind to antigens on either GPIIbflIIa or GPIbflX,'.'' although there are few data defining exact epitope localizations. As noted earlier, platelet-associated anti-GPIIb/IIIa autoantibodies bind to extracellular antigens, most of which are divalent cation-dependent.3.h Attempts to further localize antigen sites on GPIIbflIIa using large recombinant GPIIIa peptides were largely unsuccessful,'' suggesting that the epitopes were either localized on GPIIb or were dependent on an intact complex. Some plasma anti-GPIIbflIIa autoantibodies also bind to extracellular antigens,'.'.' but others bind to antigens on the GPIIIa cytoplasmic region.' Studies on anti-GPIb autoantibodies also show serum antibodies that bind to both extracellular and cytoplasmic portions of GPIb.5 Recent studies, using recombinant GPIb peptides, have localized the binding region of 6 of 16 anti-GPIb serum antibodies to a specific region on GPIb (amino acids 389 to 412). Platelet eluates from two of these patients also bound to this peptide.'' The successful use of GPIb recombinant peptides when compared with that of the negative studies with GPIIb/lIIa recombinant peptides may be in part due to the calcium-dependent heterodimeric structure of GPIIb/IIIa.
In this study, we describe the successful use of phage display to identify mimotopes of platelet autoantigens. Pa-3000 - tient ITP-I was known to have at least two distinct plasma autoantibodies. one reactive with the GPIIIa c-terminus and the other(s) to a separate, as yet undetermined, region of GPIIbflIIa. As shown by previous studies, the anti-GPIIIa c-terminus antibody binds to a synthetic peptide corresponding to amino acids 724-744 of the GPIIIa cytoplasmic region but not to two others in this area (amino acids 737-751 and 742-762).' Using the linear phage library, we identified two separate phage expressing different peptide sequences that bound strongly to the plasma autoantibody from ITP-I; one expressed the sequence REKAKW, and the other expresses PVVWKN. The binding of both phage was anti-GPIIb/IIIaspecific, because binding could be inhibited by purified GPIIb/IIIa and there was reduced binding to eluate that had been adsorbed with platelets. Fig 6. Specificity of isolated hexapeptide display phage for ITP-2 anti-GPllblllla autoantibody. Isolated fUSE5 phage (1 x 10" CFUl mL1 expressing the hexapeptide sequence RELLKM were added t o microtiter wells containing immobilized autoantibodies from patient ITP-2 alone (None), in the presence of 150 pglmL purified GPllb/llla (GPllb/lllal, or in the presence of 800 pglmL GPllla cytoplasmic tail peptide (residues 721-762). Also shown, is fUSE5 phage binding to microtiter wells containing ITP-2 antibody eluates that were preadsorbed with normal platelets (Plt Adsorbed). Bound phage were detected and quantitated as described in Materials and Methods. Results are expressed as the percentage of maximal binding to ITP-2 autoantibody in the absence any added inhibitor.
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